Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02269670
Title Phase II Study of Everolimus Beyond Progression
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Emory University
Indications

Her2-receptor negative breast cancer

Therapies

Tamoxifen

Everolimus

Megestrol acetate

Letrozole

Fulvestrant

Anastrozole

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.